Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferran Torres

Showing results (131-140 of 180) with videos related to

Pageof 18
Sort By:
Nature Communications|August 2, 2018
Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cellsErika López-Arribillaga, Verónica Rodilla, Carlota Colomer, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Journal of Hepatology|April 27, 2021
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosisCàndid Villanueva, Agustín Albillos, Joan Genescà, et al.
Hepatology (Baltimore, Md.)|October 2, 2023
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysisOana Nicoară-Farcău, Guohong Han, Marika Rudler, et al.
Nature Communications|April 27, 2026
Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 1, 2019
Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survivalCristina Solé, Elsa Solà, Patricia Huelin, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2009
Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancerVerónica Rodilla, Alberto Villanueva, Antonia Obrador-Hevia, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.
Pageof 18

Showing results (131-140 of 180) with videos related to

Sort By:
Pageof 18
Nature Communications|August 2, 2018
Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cellsErika López-Arribillaga, Verónica Rodilla, Carlota Colomer, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Journal of Hepatology|April 27, 2021
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosisCàndid Villanueva, Agustín Albillos, Joan Genescà, et al.
Hepatology (Baltimore, Md.)|October 2, 2023
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysisOana Nicoară-Farcău, Guohong Han, Marika Rudler, et al.
Nature Communications|April 27, 2026
Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 1, 2019
Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survivalCristina Solé, Elsa Solà, Patricia Huelin, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2009
Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancerVerónica Rodilla, Alberto Villanueva, Antonia Obrador-Hevia, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.
Pageof 18